Preparation of Bone Targeted Vancomycin

Technology #d-1094

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Image Gallery
Categories
Researchers
Dr. Amr Abdelgawad
Dr. Abdelgawad has a research focus on Pediatric Orthopaedics, Limb lengthening and reconstruction, Adolescent hip problems, hip preservation, bone infections and non union, trauma.
External Link (www.amrabdelgawad.com)
Dr. Eman Atef
Dr Atef had a dynamic research group and supervised multiple Masters, PhD and undergraduate students. The team focused on improving the solubility of poorly soluble small molecules using solid and lipid dosage forms as well as targeted drug delivery. Dr Atef still hold an adjunct position at MCPSH- University, and acts as the major graduate students advisor. She is currently collaborating with Texas Tech Medical School and Novartis Pharmaceutical in different research projects.
External Link (www.mcphs.edu)
Basel Karzoun
Managed By
Cameron Smith
Licensing Associate 806-834-6822
Patent Protection

US Patent Pending

This invention provides a treatment for osteomyelitis.  Typical treatment involves surgical debridement to remove dead bone tissue, followed by long-term high dose treatment with intravenous vancomycin.  This prolonged, high dose treatment often causes serious side effects.  The inventor has created a method to target vancomycin directly to bone tissue.  The antibiotic is encapsulated in a liposome.  The liposome is surface modified by adding bone targeting moiety.  The targeting moiety has a strong binding affinity for the main component of bone tissue (hydroxyapatite). 


Market Applications:

This invention will fit into the marketplace as a treatment.  The end users of this treatment will be patients with osteomyelitis.  This technology will be distributed across the market according to application and demand— developing countries have higher incidences of osteomyelitis, but the largest markets for treatments are in developed countries.


Features, Benefits, & Advantages:

• Targeted antibiotic delivery to bone tissue

• Decrease in side effects associated with traditional treatments

• Increased concentration of the antibiotic in bone tissue

• Lower necessary dose

• More effective treatment of osteomyelitis.